SNCA and synucleinopathy: These trials aim to explore various therapeutic approaches that target the underlying pathophysiology of synucleinopathies, such as neuroinflammation, synuclein aggregation, and dopaminergic dysfunction, with the ultimate goal of preventing the transition from prodromal stages to full-blown neurodegenerative disease.